Neurim Pharmaceuticals Expands Slenyto® Approval for ADHD

Neurim Pharmaceuticals Expands Slenyto® Approval for ADHD

Neurim Pharmaceuticals announces that the European Commission has granted an important extension for Slenyto®, a prolonged-release melatonin formulation indicated for the treatment of insomnia. This approval specifically addresses the needs of children diagnosed with attention deficit hyperactivity disorder (ADHD). With this significant development, Neurim is poised to offer a vital solution to families struggling with sleep issues related to ADHD.

Understanding Slenyto®

Slenyto® was initially approved within the European Union for children with autism spectrum disorder (ASD) in 2018, providing a unique pharmacological treatment option for insomnia. Following its initial success, the indication was further expanded to include children with neurogenetic disorders in 2024. Slenyto® stands out as the only authorized medication to specifically help with insomnia linked to these conditions.

Newly Extended Indication

The latest approval by the European Commission allows for the treatment of insomnia in children with ADHD aged 6 to 17 years, emphasizing the importance of addressing sleep issues as part of a comprehensive treatment approach. This development will not only help with sleep initiation but also enhance sleep maintenance and overall sleep duration. Prof. Nava Zisapel, CEO of Neurim Pharmaceuticals, highlighted the unmet needs in this area, and the extended indication for Slenyto® represents a critical step in addressing these challenges.

Expert Opinions on Slenyto®

Prominent experts such as Prof. Carmen Schroder and Prof. Oliviero Bruni have praised Slenyto®, pointing out its ability to mimic the body's natural release of melatonin, which can foster improved sleep quality for children with ADHD. They noted that many children face significant sleep disturbances, which can greatly impact their overall well-being and behavior. Slenyto® aims to tackle these issues effectively, thereby improving both child and parent quality of life.

Challenges of ADHD and Sleep Disorders

Sleep problems are prevalent among children with ADHD, affecting up to 70% of this population. Such sleep disruptions can begin at an early age, often surfacing before a formal ADHD diagnosis. Research shows that inadequate sleep in these children can worsen ADHD symptoms and negatively impact daily functioning for both the children and their caregivers. Thus, enhancing sleep hygiene is a critical component of management strategies for ADHD.

Behavioral Interventions and Pharmacological Solutions

Organizations currently recommend behavioral sleep interventions as a primary approach for managing insomnia among pediatric ADHD cases. However, Slenyto® presents a novel pharmacological option for families who seek an additional tool in addressing these sleep issues, enhancing both initiation and maintenance of sleep.

Exploring the Composition and Efficacy of Slenyto®

Slenyto® features a tailored formulation of melatonin specifically crafted for children, making it easier to swallow and ensuring that it meets the unique needs of children suffering from insomnia. This innovative design allows Slenyto® to effectively deliver melatonin across the night, replicating the melatonin release profile typical in healthy children. Clinical studies on Slenyto® have demonstrated improvements in sleep onset, duration, and overall quality of sleep.

Impact on Behavioral Outcomes

Beyond sleep quality, positive effects of Slenyto® have been observed on externalizing behavior in children, emphasizing the importance of uninterrupted sleep. Enhanced sleep patterns have been linked to better behavioral outcomes, which in turn contribute to greater parent satisfaction and improved quality of life. The findings suggest that Slenyto® could significantly assist in the management of ADHD and its associated sleep disturbances.

About Neurim Pharmaceuticals

Neurim Pharmaceuticals Ltd. is a pioneering company focused on drug discovery and development centered on neuroscience. With its flagship product, CIRCADIN®, already helping patients over 55 with insomnia, Neurim continues to advance its product pipeline that targets central nervous system disorders. The successful expansion of Slenyto® underscores Neurim's commitment to innovative solutions in pediatric sleep health.

For more information regarding Neurim Pharmaceuticals and its offerings, visit their official site.

Frequently Asked Questions

What is Slenyto® and its purpose?

Slenyto® is a prolonged-release melatonin formulation used to treat insomnia in children with ADHD and other neurodevelopmental disorders.

What age group is approved for Slenyto® use in treating ADHD?

Slenyto® is approved for children and adolescents aged 6 to 17 years with ADHD who face sleep difficulties.

How does Slenyto® differ from other sleep aids?

Slenyto® specifically mimics the body's natural melatonin release pattern, making it suitable for children with neurodevelopmental disorders.

What impact does Slenyto® have on overall health?

Beyond improving sleep quality, Slenyto® has been associated with better behavioral outcomes in children, enhancing both family well-being and parenting satisfaction.

What is Neurim Pharmaceuticals' focus?

Neurim Pharmaceuticals is focused on developing innovative treatments for sleep disorders and continues to expand its product pipeline aimed at CNS disorders.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.